Can GKT137831 – a NOX Inhibitor – Stop Liver Fibrosis?
New drug successfully halts fibrosis in animal model of liver disease
August 7, 2012 in Diseases, Conditions, Syndromes
A study published in the online journal Hepatology reports a potential new NADPH oxidase (NOX) inhibitor therapy for liver fibrosis, a scarring process associated with chronic liver disease that can lead to loss of liver function.
“While numerous studies have now demonstrated that advanced liver fibrosis in patients and in experimental rodent models is reversible, there is currently no effective therapy for patients,” said principal investigator David A. Brenner, MD, vice chancellor for Health Sciences and dean of the School of Medicine at the University of California, San Diego. “This new study provides important validation of the role of NOX in liver fibrosis, and suggests that a NOX inhibitor could provide an effective treatment for this devastating disease.”
Continue reading this entire article:
Pool Chemicals and Hepatitis C
Heart Problem Pauses Hepatitis C Drug Study